Comprehensive review of palliative care for Glioblastoma

Radhika Korde; Mohd Basheeruddin

Keywords:

Glioblastoma (GBM)

Palliative care

Symptom management

Advance care planning (ACP)

Neurocognitive decline

Hospice care

Abstract

Glioblastoma (GBM) stands out as the predominant and highly aggressive malignant brain tumour affecting adults. Initial therapeutic interventions involve a combination of surgical removal, radiation, and chemotherapy. Substantial progress in comprehending the molecular abnormalities of GBM and linked cellular signalling pathways has unveiled prospects for novel treatments targeting both recurrent and newly diagnosed cases. Promising advancements, such as tumor-treating fields (TTFields) and immunotherapy, offer prospects for improved survival outcomes. Although glioblastoma is treated with surgery, radiation, and chemotherapy, the cancer is incurable and has a terrible prognosis. Glioblastoma patients may have growing neurological impairments, headaches and sleepiness due to elevated intracranial pressure, incontinence, seizures, and gradual cognitive loss during the disease. These people suffer from both cancer and a degenerative brain condition. This might significantly impede their capacity to decide on their course of therapy. Thus, early involvement of glioblastoma patients in treatment decisions regarding their future care, including end-of-life care (EOL) is needed and may be accomplished through Advance Care Planning (ACP).
References
1. Gimple RC, Bhargava S, Dixit D, Rich JN: Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer. Genes Dev. 2019, 33:591–609. 10.1101/gad.324301.119
2. Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M: Management of glioblastoma: State of the art and future directions. CA Cancer J Clin. 2020, 70:299–312. 10.3322/caac.21613
3. Wu A, Ruiz Colón G, Aslakson R, Pollom E, Patel CB: Palliative Care Service Utilization and Advance Care Planning for Adult Glioblastoma Patients: A Systematic Review. Cancers (Basel). 2021, 13:2867. 10.3390/cancers13122867
4. Le Rhun E, Preusser M, Roth P, et al.: Molecular targeted therapy of glioblastoma. Cancer Treat Rev. 2019, 80:101896. 10.1016/j.ctrv.2019.101896
5. Stec NE, Walbert T: Neuro-oncology and supportive care: the role of the neurologist. Neurol Sci. 2022, 43:939–50. 10.1007/s10072-021-05862-3
6. Davis ME: Glioblastoma: Overview of Disease and Treatment. Clin J Oncol Nurs. 2016, 20:S2–8. 10.1188/16.CJON.S1.2-8
7. Crooms RC, Johnson MO, Leeper H, Mehta A, McWhirter M, Sharma A: Easing the Journey-an Updated Review of Palliative Care for the Patient with High-Grade Glioma. Curr Oncol Rep. 2022, 24:501–15. 10.1007/s11912-022-01210-6
8. Chandrasekar G, Bansal VS, Panigrahi M, Kitambi SS: An overview of targets and therapies for glioblastoma multiforme. J Cancer Res Ther. 2022, 18:591–8. 10.4103/jcrt.jcrt_1324_21
9. Witteler J, Schild SE, Rades D: Palliative Radiotherapy of Primary Glioblastoma. In Vivo. 2021, 35:483–7. 10.21873/invivo.12282
10. Fritz L, Dirven L, Reijneveld JC, Koekkoek JAF, Stiggelbout AM, Pasman HRW, Taphoorn MJB: Advance Care Planning in Glioblastoma Patients. Cancers (Basel). 2016, 8:102. 10.3390/cancers8110102
11. Barzegar Behrooz A, Talaie Z, Jusheghani F, Łos MJ, Klonisch T, Ghavami S: Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma. Int J Mol Sci. 2022, 23:1353. 10.3390/ijms23031353
12. Wu A, Ugiliweneza B, Wang D, Hsin G, Boakye M, Skirboll S: Trends and outcomes of early and late palliative care consultation for adult patients with glioblastoma: A SEER-Medicare retrospective study. Neurooncol Pract. 2022, 9:299–309. 10.1093/nop/npac026
13. Dixit S, Pueschel JK, Wallace JM, Bolletino RC, Block KI: Integrative tumor board: glioblastoma multiforme. Integr Cancer Ther. 2004, 3:149–72. 10.1177/1534735404264737
14. Saeed H, Tseng YD, Lo SS: Narrative review of palliative hypofractionated radiotherapy for high grade glioma. Ann Palliat Med. 2021, 10:846–62. 10.21037/apm-20-1246
15. Pace A, Tanzilli A, Benincasa D: Prognostication in brain tumors. Handb Clin Neurol. 2022, 190:149–61. 10.1016/B978-0-323-85029-2.00001-4
16. Colen CB, Allcut E: Quality of life and outcomes in glioblastoma management. Neurosurg Clin N Am. 2012, 23:507–13. 10.1016/j.nec.2012.04.010
17. Lewitzki V, Klement RJ, Kosmala R, Lisowski D, Flentje M, Polat B: Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma. Radiat Oncol. 2019, 14:227. 10.1186/s13014-019-1427-5
18. Ameratunga M, Pavlakis N, Wheeler H, Grant R, Simes J, Khasraw M: Anti-angiogenic therapy for high-grade glioma. Cochrane Database Syst Rev. 2018, 11:CD008218. 10.1002/14651858.CD008218.pub4
19. Lee A, Arasaratnam M, Chan DLH, Khasraw M, Howell VM, Wheeler H: Anti-epidermal growth factor receptor therapy for glioblastoma in adults. Cochrane Database Syst Rev. 2020, 5:CD013238. 10.1002/14651858.CD013238.pub2
20. Byrne A, Torrens-Burton A, Sivell S, et al.: Early palliative interventions for improving outcomes in people with a primary malignant brain tumour and their carers. Cochrane Database Syst Rev. 2022, 1:CD013440. 10.1002/14651858.CD013440.pub2
21. Honea N: End-of-Life Care for Patients with Glioma. Semin Oncol Nurs. 2018, 34:553–68. 10.1016/j.soncn.2018.10.013
22. McKinnon C, Nandhabalan M, Murray SA, Plaha P: Glioblastoma: clinical presentation, diagnosis, and management. BMJ. 2021, 374:n1560. 10.1136/bmj.n1560
23. Jiang C, Mogilevsky C, Belal Z, Kurtz G, Alonso-Basanta M: Hypofractionation in Glioblastoma: An Overview of Palliative, Definitive, and Exploratory Uses. Cancers (Basel). 2023, 15:5650. 10.3390/cancers15235650
24. Goldbrunner R, Ruge M, Kocher M, Lucas CW, Galldiks N, Grau S: The Treatment of Gliomas in Adulthood. Dtsch Arztebl Int. 2018, 115:356–64. 10.3238/arztebl.2018.0356
25. Garside R, Pitt M, Anderson R, et al.: The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess. 2007, 11:iii–iv, ix–221. 10.3310/hta11450
26. Shah AH, Mahavadi A, Di L, et al.: Survival benefit of lobectomy for glioblastoma: moving towards radical supramaximal resection. J Neurooncol. 2020, 148:501–8. 10.1007/s11060-020-03541-5
27. Batchelor TT, Byrne TN: Supportive care of brain tumor patients. Hematol Oncol Clin North Am. 2006, 20:1337–61. 10.1016/j.hoc.2006.09.013
28. Halatsch M-E: Special Issue: Principal Challenges in the Adjuvant Treatment of Glioblastoma. Biomedicines. 2023, 11:1881. 10.3390/biomedicines11071881
29. Vaz-Salgado MA, Villamayor M, Albarrán V, et al.: Recurrent Glioblastoma: A Review of the Treatment Options. Cancers (Basel). 2023, 15:4279. 10.3390/cancers15174279
30. Wee CW: Radiotherapy for Newly Diagnosed Glioblastoma in the Elderly: What Is the Standard? Brain Tumor Res Treat. 2022, 10:12–21. 10.14791/btrt.2022.10.e34
31. Biau J, Chautard E, De Schlichting E, et al.: Radiotherapy plus temozolomide in elderly patients with glioblastoma: a ‘real-life’ report. Radiat Oncol. 2017, 12:197. 10.1186/s13014-017-0929-2

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

How to cite

Korde, R., & Basheeruddin, M. (2024). Comprehensive review of palliative care for Glioblastoma. Multidisciplinary Reviews, (| Accepted Articles). Retrieved from https://malque.pub/ojs/index.php/mr/article/view/4438

[1] Gimple RC, Bhargava S, Dixit D, Rich JN: Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer. Genes Dev. 2019, 33:591–609. 10.1101/gad.324301.119

[2] Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M: Management of glioblastoma: State of the art and future directions. CA Cancer J Clin. 2020, 70:299–312. 10.3322/caac.21613

[3] Wu A, Ruiz Colón G, Aslakson R, Pollom E, Patel CB: Palliative Care Service Utilization and Advance Care Planning for Adult Glioblastoma Patients: A Systematic Review. Cancers (Basel). 2021, 13:2867. 10.3390/cancers13122867

[4] Le Rhun E, Preusser M, Roth P, et al.: Molecular targeted therapy of glioblastoma. Cancer Treat Rev. 2019, 80:101896. 10.1016/j.ctrv.2019.101896

[5] Stec NE, Walbert T: Neuro-oncology and supportive care: the role of the neurologist. Neurol Sci. 2022, 43:939–50. 10.1007/s10072-021-05862-3

[6] Davis ME: Glioblastoma: Overview of Disease and Treatment. Clin J Oncol Nurs. 2016, 20:S2–8. 10.1188/16.CJON.S1.2-8

[7] Crooms RC, Johnson MO, Leeper H, Mehta A, McWhirter M, Sharma A: Easing the Journey-an Updated Review of Palliative Care for the Patient with High-Grade Glioma. Curr Oncol Rep. 2022, 24:501–15. 10.1007/s11912-022-01210-6

[8] Chandrasekar G, Bansal VS, Panigrahi M, Kitambi SS: An overview of targets and therapies for glioblastoma multiforme. J Cancer Res Ther. 2022, 18:591–8. 10.4103/jcrt.jcrt_1324_21

[9] Witteler J, Schild SE, Rades D: Palliative Radiotherapy of Primary Glioblastoma. In Vivo. 2021, 35:483–7. 10.21873/invivo.12282

[10] Fritz L, Dirven L, Reijneveld JC, Koekkoek JAF, Stiggelbout AM, Pasman HRW, Taphoorn MJB: Advance Care Planning in Glioblastoma Patients. Cancers (Basel). 2016, 8:102. 10.3390/cancers8110102

[11] Barzegar Behrooz A, Talaie Z, Jusheghani F, Łos MJ, Klonisch T, Ghavami S: Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma. Int J Mol Sci. 2022, 23:1353. 10.3390/ijms23031353

[12] Wu A, Ugiliweneza B, Wang D, Hsin G, Boakye M, Skirboll S: Trends and outcomes of early and late palliative care consultation for adult patients with glioblastoma: A SEER-Medicare retrospective study. Neurooncol Pract. 2022, 9:299–309. 10.1093/nop/npac026

[13] Dixit S, Pueschel JK, Wallace JM, Bolletino RC, Block KI: Integrative tumor board: glioblastoma multiforme. Integr Cancer Ther. 2004, 3:149–72. 10.1177/1534735404264737

[14] Saeed H, Tseng YD, Lo SS: Narrative review of palliative hypofractionated radiotherapy for high grade glioma. Ann Palliat Med. 2021, 10:846–62. 10.21037/apm-20-1246

[15] Pace A, Tanzilli A, Benincasa D: Prognostication in brain tumors. Handb Clin Neurol. 2022, 190:149–61. 10.1016/B978-0-323-85029-2.00001-4

[16] Colen CB, Allcut E: Quality of life and outcomes in glioblastoma management. Neurosurg Clin N Am. 2012, 23:507–13. 10.1016/j.nec.2012.04.010

[17] Lewitzki V, Klement RJ, Kosmala R, Lisowski D, Flentje M, Polat B: Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma. Radiat Oncol. 2019, 14:227. 10.1186/s13014-019-1427-5

[18] Ameratunga M, Pavlakis N, Wheeler H, Grant R, Simes J, Khasraw M: Anti-angiogenic therapy for high-grade glioma. Cochrane Database Syst Rev. 2018, 11:CD008218. 10.1002/14651858.CD008218.pub4

[19] Lee A, Arasaratnam M, Chan DLH, Khasraw M, Howell VM, Wheeler H: Anti-epidermal growth factor receptor therapy for glioblastoma in adults. Cochrane Database Syst Rev. 2020, 5:CD013238. 10.1002/14651858.CD013238.pub2

[20] Byrne A, Torrens-Burton A, Sivell S, et al.: Early palliative interventions for improving outcomes in people with a primary malignant brain tumour and their carers. Cochrane Database Syst Rev. 2022, 1:CD013440. 10.1002/14651858.CD013440.pub2

[21] Honea N: End-of-Life Care for Patients with Glioma. Semin Oncol Nurs. 2018, 34:553–68. 10.1016/j.soncn.2018.10.013

[22] McKinnon C, Nandhabalan M, Murray SA, Plaha P: Glioblastoma: clinical presentation, diagnosis, and management. BMJ. 2021, 374:n1560. 10.1136/bmj.n1560

[23] Jiang C, Mogilevsky C, Belal Z, Kurtz G, Alonso-Basanta M: Hypofractionation in Glioblastoma: An Overview of Palliative, Definitive, and Exploratory Uses. Cancers (Basel). 2023, 15:5650. 10.3390/cancers15235650

[24] Goldbrunner R, Ruge M, Kocher M, Lucas CW, Galldiks N, Grau S: The Treatment of Gliomas in Adulthood. Dtsch Arztebl Int. 2018, 115:356–64. 10.3238/arztebl.2018.0356

[25] Garside R, Pitt M, Anderson R, et al.: The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess. 2007, 11:iii–iv, ix–221. 10.3310/hta11450

[26] Shah AH, Mahavadi A, Di L, et al.: Survival benefit of lobectomy for glioblastoma: moving towards radical supramaximal resection. J Neurooncol. 2020, 148:501–8. 10.1007/s11060-020-03541-5

[27] Batchelor TT, Byrne TN: Supportive care of brain tumor patients. Hematol Oncol Clin North Am. 2006, 20:1337–61. 10.1016/j.hoc.2006.09.013

[28] Halatsch M-E: Special Issue: Principal Challenges in the Adjuvant Treatment of Glioblastoma. Biomedicines. 2023, 11:1881. 10.3390/biomedicines11071881

[29] Vaz-Salgado MA, Villamayor M, Albarrán V, et al.: Recurrent Glioblastoma: A Review of the Treatment Options. Cancers (Basel). 2023, 15:4279. 10.3390/cancers15174279

[30] Wee CW: Radiotherapy for Newly Diagnosed Glioblastoma in the Elderly: What Is the Standard? Brain Tumor Res Treat. 2022, 10:12–21. 10.14791/btrt.2022.10.e34

[31] Biau J, Chautard E, De Schlichting E, et al.: Radiotherapy plus temozolomide in elderly patients with glioblastoma: a ‘real-life’ report. Radiat Oncol. 2017, 12:197. 10.1186/s13014-017-0929-2

Abstract

References

How to cite